A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent breast cancers

Trial Profile

A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent breast cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Montanide ISA-51 (Primary) ; Picibanil (Primary) ; Survivin 2B peptide vaccine (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 30 May 2012 Additional lead investigator identified as reported by University Hospital Medical Information Network - Japan record.
    • 21 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top